{"analyses":[{"ciLowerLimit":"0.82","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.15","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.3802","paramType":"Hazard Ratio (HR)","paramValue":"0.97","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.3","upperLimit":"11.4","value":"9.9"},{"groupId":"OG001","lowerLimit":"9.1","upperLimit":"12.6","value":"10.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"312"},{"groupId":"OG001","value":"310"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as the time from randomization to death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 200 mg IV every Q3W for up to 35 administrations (up to \\~2 years).","id":"OG000","title":"Pembrolizumab"},{"description":"Participants received capecitabine, eribulin, gemcitabine, or vinorelbine as single agent chemotherapy chosen by the treating physician (Treatment of Physician's Choice, TPC) in accordance with local regulations and guidelines.","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"All participants who were included in a treatment group at randomization","reportingStatus":"POSTED","timeFrame":"Up to approximately 36 months (through Final Analysis database cutoff date of 11-April-2019)","title":"Overall Survival in All Participants","type":"PRIMARY","unitOfMeasure":"Months"}